Nektar Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.456; its P/E ratio is -0.64; Nektar Therapeutics is scheduled to report earnings on May 8, 2024, and the estimated EPS forecast is $-0.19. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 23.89M	$ 24.14M	$ 20.50M	$ 21.59M	$ 22.02M
Gross Profit	$ 16.60M	$ 11.71M	$ 13.51M	$ 14.53M	$ -120.14M
EBIT	$ -42.11M	$ -45.90M	$ -51.17M	$ -137.08M	$ -82.77M
EBITDA	$ -55.31M	$ -44.20M	$ -49.00M	$ -134.78M	$ -82.02M
Net Income Common Stockholders	$ -42.08M	$ -45.84M	$ -51.12M	$ -137.02M	$ -59.69M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 303.62M	$ 372.66M	$ 409.43M	$ 456.83M	$ 504.98M
Total Assets	$ 398.03M	$ 442.24M	$ 494.28M	$ 561.74M	$ 710.60M
Total Debt	$ 117.78M	$ 121.29M	$ 124.75M	$ 128.16M	$ 131.50M
Net Debt	$ -185.84M	$ -251.37M	$ -284.68M	$ -328.67M	$ -373.48M
Total Liabilities	$ 267.05M	$ 282.88M	$ 297.32M	$ 320.88M	$ 343.96M
Stockholders Equity	$ 130.99M	$ 159.37M	$ 196.96M	$ 240.87M	$ 366.64M
Cash Flow	-
Free Cash Flow	$ -47.28M	$ -40.91M	$ -51.68M	$ -52.35M	$ -45.02M
Operating Cash Flow	$ -47.05M	$ -42.12M	$ -51.52M	$ -51.92M	$ -57.70M
Investing Cash Flow	$ 17.38M	$ 56.41M	$ 25.17M	$ 40.60M	$ 40.01M
Financing Cash Flow	$ 12.00K	-	$ 18.00K	-	$ 103.00K

Currency in USD

Nektar Therapeutics Earnings and Revenue History

Income Statement >

Nektar Therapeutics Debt to Assets

Balance Sheet >

Nektar Therapeutics Cash Flow

Cash Flow >

Nektar Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing